Sun Pharma stock: Informist cites INR 2,148 average target for Sun Pharma stock

Published on 10/19/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 30, 2026. Sun Pharma stock costs INR 1,743.00 on October 19, 2026, down 0.90 percent versus the NSE close.

Analyst view and dates

Informist cited an INR 2,148 average target across 18 research reports on October 17, 2026.
Sun Pharma is scheduled to announce its September-quarter results on October 30, 2026.
Sun Pharma stock stood at INR 1,743.00 at 3:29 p.m. IST on October 19, 2026, down 0.90 percent versus the NSE close of October 16, 2026.
The price-to-earnings ratio was 34.58 on October 19, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Informist reported on October 17, 2026, that 18 research reports carried an average Sun Pharma target of INR 2,148, 23.24 percent above the October 19 price of INR 1,743.00. The same report said 16 of those reports carried a buy or equivalent rating. Sun Pharma stock stood at INR 1,743.00 at 3:29 p.m. IST on October 19, 2026, down 0.90 percent versus the NSE close of October 16, 2026.

Results arrive on October 30

The next scheduled corporate milestone is the September-quarter earnings release on October 30, 2026. EconoTimes reported that Sun Pharma will announce results for the quarter ended September 30 and hold an earnings call on the same date. Sun Pharma's investor page separately lists July to September under the second quarter of fiscal 2027.

Price position on October 19

The NSE quote was INR 1,743.00, with volume of 829,135 shares against an average of 1,820,043. That is 54.45 percent below the average volume. The 52-week range was INR 1,583.70 to INR 2,046.90, leaving the stock 10.06 percent above its low and 14.85 percent below its high.

Valuation and analyst view

Sun Pharma had a market capitalization of INR 4.2 trillion and a price-to-earnings ratio of 34.58 on October 19, 2026. The average target of INR 2,148 implies 23.24 percent upside from the current NSE price, while the lowest target cited by Informist was INR 1,848 and the highest was INR 2,400. The range shows why the October 30 results matter: the consensus remains constructive, but the estimates also leave room for a wide range of outcomes.

Comparison with peers

Sun Pharma: minus 0.90 percent, P/E 34.58, market capitalization INR 4.2 trillion.

Cipla (NSE, INR): minus 0.08 percent, P/E 31.75, market capitalization INR 1.1 trillion.

Dr. Reddy's Laboratories (NSE, INR): plus 0.77 percent, P/E 31.29, market capitalization INR 1.0 trillion.

What the next report will test

Sun Pharma's September-quarter report will test whether domestic formulations and specialty medicines can offset pressure in the US generics business. Informist's September-quarter consensus projected revenue of INR 157.69 billion and net profit of INR 31.18 billion, while the average earnings-before-interest, tax, depreciation and amortization estimate was INR 44.29 billion. The report also put the expected margin range at 26.30 percent to 29.30 percent, below 31.30 percent a year earlier.

The stock's market value and valuation multiple leave the October 30 update as the next concrete measure of execution. A target above the current price does not remove the earnings risk reflected in the wide forecast range.